Trial Profile
A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
- Indications Photodamage; Skin aging
- Focus Adverse reactions
- Sponsors Stemedica Cell Technologies
- 27 Oct 2022 Planned End Date changed from 1 Dec 2022 to 31 Dec 2024.
- 27 Oct 2022 Planned primary completion date changed from 1 Apr 2022 to 30 Apr 2024.
- 27 Oct 2022 Status changed from suspended to active, no longer recruiting.